Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant

Part of paid clinical trials in Palo Alto, California.

Sponsor
Andrew Rezvani
Study ID
NCT03267186
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Ibrutinib — DRUG
    Given PO
  • Laboratory Biomarker Analysis — OTHER
    Correlative studies

Study Details

This phase II trial studies how well ibrutinib works in preventing acute leukemia in patients after reduced-intensity conditioning and stem cell transplant. Ibrutinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Key Dates

Start date
Sep 12, 2017
Status verified
Jul 2023
Primary completion
Apr 30, 2021
Completion
Apr 30, 2021

Study Design

Enrollment
8 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Prevention (ibrutinib)
    Beginning 60-90 days after allogeneic HCT, patients receive ibrutinib PO QD for up to 18 months post-transplant in the absence of disease progression or unacceptable toxicity.

Primary Outcome Measure

Number of Participants With Relapsed Leukemia [ Time Frame: Up to 18 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
Stanford University, School of MedicinePalo AltoCalifornia94304-

Find similar trials in Palo Alto, CA

By condition
Leukemia (other)
By specialty
OncologyBlood cancer
By research site
Stanford University, School of Medicine· Palo Alto, CA

Related Studies